NORTHFIELD LABORATORIES INC /DE/ Form SC 13G August 08, 2003

UNITED STATES

WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934 (Amendment No)*
Northfield Laboratories Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
666135108
(CUSIP Number)
July 28, 2003
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
_ Rule 13d-1(b)
X Rule 13d-1(c)
_ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP	No.	666135108		13G	Page	2	of	 6 	Page	s 	
1		NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (Entities o Michael A. Roth and Brian J. Stark, as joint filers pur							Rule	 13D-1	(k)
2		CHECK THE APPRO		BOX IF A MEMBER OF A GROU							_ _ _
3		SEC USE ONLY									
4		CITIZENSHIP OF PLACE OF ORGANIZATION United States of America									
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 1,160,714								
		-	6	SHARED VOTING POWER							
			7	SOLE DISPOSITIVE POWER 1,160,714							
		-	8	SHARED DISPOSITIVE POWN							
	9	AGGREGATE AN	MOUNT BE	ENEFICIALLY OWNED BY EACH	REPORT	ING	PER	SON			
		1,160,714									
1(0	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* _ Not applicable.									
1:	 1	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)									

12 TYPE OF REPORTING PERSON*

ΙN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

SCHEDULE 13G	Page 3 of 6 Pages August 7, 2003			
Item 1(a).	Name of Issuer.			
Item 1(b).	Northfield Laboratories Inc. Address of Issuer's Principal Executive Offices.			
	1560 Sherman Avenue Suite 1000 Evanston, IL 60201-4800			
Item 2(a).	Name of Person Filing.			
	Michael A. Roth and Brian J. Stark, as joint filers			
Item 2(b).	Address of Principal Business Office or, if None,			
	Residence.			
	3600 South Lake Drive St. Francis, WI 53235			
Item 2(c).	Citizenship.			
	United States of America			
Item 2(d).	Title of Class of Securities.			
	Common Stock			
Item 2(e).	CUSIP Number.			
	666135108			
Item 3. If this Statement is Filed pursuant to Rule 13d-1(b), or				
	13d-2(b) or (c), Check Whether the Person Filing is a:			
	(a) _ Broker or dealer registered under Section 15 of the Exchange Act.			
	(b) _ Bank as defined in Section 3(a)(6) of the			

Exchange Act. Insurance company as defined in Section 3(a) (C) 1_1 (19) of the Exchange Act. (e) 1_1 Investment company registered under Section 8 of the Investment Company Act. An investment advisor in accordance with (f) 1 1 Rule 13d-1(b)(1)(ii)(E); Page 4 of 6 Pages August 7, 2003 SCHEDULE 13G An employee benefit plan or endowment fund (g) 1_1 in accordance with Rule 13d-1(b)(1)(ii)(F); A parent holding company or control person (h) 1_1 in accordance with Rule 13d-1(b)(1)(ii)(G) (i) 1_1 A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; A churc h plan that is excluded from the (j) 1_1 definition of an investment company under Section 3(c)(14) of the Investment Company

(ii)(J)

(k)

(iv)

1_1

If this statement is filed pursuant to Rule 13d-1(c), check this box. |X|

Group, in accordance with Rule 13d-1(b)(1)

Item 4.	Ownership.	
	(a)	Amount beneficially owned: 1,160,714*
	(b)	Percent of class: 7.1%*
	(c)	Number of shares as to which such person has:
	(i)	Sole power to vote or to direct the vote 1,160,714*
	(ii)	Shared power to vote or to direct the vote 0
	(iii)	Sole power to dispose or to direct the disposition of 1,160,714 * ,

*The foregoing amounts of shares and percentage represent the combined indirect holdings of Michael A. Roth and Brian J. Stark, as joint filers. All of the foregoing shares are held directly by SF Capital Partners, Ltd., a British Virgin Islands company ("SF Capital") which acquired 892,857 shares and the

Shared power to dispose or direct the disposition of

right to purchase an additional 267,857 shares within 60 days after July 28, 2003. Messrs. Roth and Stark are the founding members and direct the management of Staro Asset Management, L.L.C., a Wisconsin limited liability company ("Staro") which acts as investment manager and has sole power to direct the management of SF Capital. Through Staro, Messrs. Roth and Stark possess sole voting and dispositive power over all of the foregoing shares. Based upon the 16,426,589 shares of Common Stock issued and outstanding as of July 28, 2003, as reported by the Issuer to SF Capital (which amount

Page 5 of 6 Pages August 7, 2003

SCHEDULE 13G

includes the 14,265,875 shares reported in the Issuer's Form 10-Q for the period ended February 28, 2003 plus the 1,892,857 shares sold, along with options exercisable within 60 days to purchase an additional 567,857 shares, as of July 28, 2003 pursuant to the Issuer's Registration Statement on Form S-3 filed with the SEC on June 27, 2003, as supplemented), for the purposes of Rule 13d-3 under the Securities Exchange Act of 1934, Messrs. Roth and Stark may be deemed to be the beneficial owners of 1,160,714 shares of Common Stock which represents 7.1% of the Issuer's issued and outstanding shares of Common Stock.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

Page 6 of 6 Pages August 7, 2003

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 7, 2003

/s/ Michael A. Roth
----Michael A. Roth

/s/ Brian J. Stark
-----Brian J. Stark

EXHIBIT 1

AGREEMENT AS TO JOINT FILING

Dated: August 7, 2003

The undersigned hereby agree that the Schedule 13G with respect to Northfield Laboratories Inc. dated as of the date hereof, is filed on behalf of each of the undersigned jointly pursuant to Rule 13d-1(k).

/s/ Michael A. Roth

Michael A. Roth

/s/ Brian J. Stark
-----Brian J. Stark

\\NYCNT02\GDRIVE\EDGAR\EUGHETTA.NLI13G-0729.TXT 08/07/03 4:14 PM